Product Introduction :
Talazoparib is a PARP inhibitor developed by Pfizer. It is the fourth PARP inhibitor approved by the U.S. FDA so far. Talazoparib is indicated for the treatment of patients with HER2-negative advanced breast cancer carrying germline BRCA mutations. In breast cancer, BRCA1/2 gene mutations account for 5% to 10%. Patients with BRCA1 or BRCA2 germline gene mutations carry specific DNA repair defects, so they are particularly sensitive to PARP inhibitors that can hinder DNA repair. Talazoparib is the most potent PARP inhibitor; different from the previous PARP inhibitors, it can exert efficacy at a much low concentration. So far, the EMBRACA study is the largest clinical trial of PARP monotherapy in patients with HER2-negative advanced breast cancer carrying germline BRCA mutations. The study results showed that patients who received treatment with talazopanib had a significantly prolonged PFS. The risk of disease progression was reduced by 46%, and the objective response rate was 62.6%.
Indications :
Talazoparib is indicated for the treatment of patients with HER2-negative locally advanced or metastatic breast cancer carrying harmful or suspected harmful germline BRCA gene mutations (gBRCAm).
Administration and Dosage :
Recommended dose: 1mg, once a day.
